EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeted Sequencing-Based Re-Evaluation of Candidate Immunogenetic Variants for Biologic Treatment Response and Difficult-to-Treat Rheumatoid Arthritis

Alena I Zagrebneva iD, Elena N Simonova, Yuliya A Gavrikova iD, Vladislav V Dolgov iD, Anastasiia A Buianova iD, Ekaterina D Glumova, Maria I Tubalova iD, Galina S Koksharova iD, Artem R Nurislamov iD, Vadim I Mazurov

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27198800 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Alena I Zagrebneva und 9 weiteren Autor:innen. Beteiligte Einrichtung: Organizational and Methodological Department, North-Western State Medical University Named After I.I. Mechnikov, 41, Kirochnaya St., Saint Petersburg…. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health of the Russian Federation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Genetic determinants of response to biologic disease-modifying antirheumatic drugs (bDMARDs) in rheumatoid arthritis (RA) remain insufficiently characterized. We developed a targeted sequencing panel of candidate immunogenetic variants identified through a literature review and evaluated associations with response to TNF-α inhibitors, response to IL-6 inhibitors, and difficult-to-treat RA (D2TRA). Whole-blood DNA was sequenced using custom hybridization capture on a DNBSEQ-G400 platform (2 × 150 bp). Reads were aligned to hg38 using BWA-MEM, and variants were called with GATK HaplotypeCaller. After quality control, the D2TRA analysis included 154 patients (59 D2TRA and 95 non-D2TRA); drug-response analyses included 66 anti-TNF patients (26 responders, 40 non-responders) and 69 anti-IL-6 patients (29 responders, 40 non-responders). Treatment-response associations were assessed using unadjusted allelic chi-square tests with multiple-testing correction; D2TRA was analyzed using logistic regression adjusted for age, sex, and body mass index. For IL-6 inhibitor response, rs11656130/MAP2K6 (p = 0.0163; FDR = 0.3704) and rs4910008/GALNT18 (p = 0.0212; FDR = 0.3704) were identified, while rs7767069/LINC02549 was associated with TNF-α inhibitor response (p = 0.0171; FDR = 0.5968). For D2TRA, rs1813443 in CNTN5 (OR = 1.85, p = 0.017) and rs12081765, an intergenic variant near LMX1A/RXRG (OR = 0.59, p = 0.028), were nominally associated; neither association remained significant after multiple-testing correction. With the current sample sizes, the study could detect only large genetic effects, and was underpowered for these after Bonferroni correction (α = 0.00143). The findings highlight the limited reproducibility of candidate pharmacogenetic markers in RA and provide a targeted panel and analytical framework for larger replication studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidAntirheumatic AgentsHumansFemaleMaleMiddle AgedPolymorphism, Single NucleotideTumor Necrosis Factor-alphaTreatment OutcomeAgedInterleukin-6Treatment Effect Heterogeneity

Stichwörter der Autor:innen

IL-6 inhibitorsTNF-α inhibitorsbiologic DMARDscandidate-variant analysisdifficult-to-treat RApharmacogeneticsrheumatoid arthritistargeted sequencing

Substanzen

Antirheumatic AgentsTumor Necrosis Factor-alphaInterleukin-6

Autor:innen und Institutionen

  • Organizational and Methodological Department, North-Western State Medical University Named After I.I. Mechnikov, 41, Kirochnaya St., Saint Petersburg 191015, Russia.
  • Moscow Clinical Research Center "Hospital No. 52", 3, Pekhotnaya St., Moscow 123182, Russia.
  • Research Institute of Healthcare Organization and Medical Management, Moscow Department of Healthcare, 30, Bolshaya Tatarskaya St., Moscow 115184, Russia.
  • Russian Clinical Research Center of Gerontology, Pirogov Russian National Research Medical University of the Ministry of Healthcare of the Russian Federation, Moscow 129226, Russia.
  • Institute of Cytology and Genetics, Russian Academy of Sciences, Novosibirsk 630090, Russia.
  • Clinical Rheumatology Hospital No. 25 Named After V.A. Nasonova, 30, Bolshaya Podyacheskaya St., Saint Petersburg 190068, Russia.

ORCID-Profile: Alena I Zagrebneva, Yuliya A Gavrikova, Vladislav V Dolgov, Anastasiia A Buianova, Maria I Tubalova, Galina S Koksharova, Artem R Nurislamov

Förderung

  • Ministry of Health of the Russian Federation

Zitieren

APA

Zagrebneva, A. I., Simonova, E. N., Gavrikova, Y. A., Dolgov, V. V., Buianova, A. A., Glumova, E. D., Tubalova, M. I., Koksharova, G. S., Nurislamov, A. R., & Mazurov, V. I. (2026). Targeted Sequencing-Based Re-Evaluation of Candidate Immunogenetic Variants for Biologic Treatment Response and Difficult-to-Treat Rheumatoid Arthritis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27198800

Vancouver

Zagrebneva AI, Simonova EN, Gavrikova YA, Dolgov VV, Buianova AA, Glumova ED, et al. Targeted Sequencing-Based Re-Evaluation of Candidate Immunogenetic Variants for Biologic Treatment Response and Difficult-to-Treat Rheumatoid Arthritis. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27198800

BibTeX
@article{Zagrebneva2026,
  author = {Zagrebneva, Alena I and Simonova, Elena N and Gavrikova, Yuliya A and Dolgov, Vladislav V and Buianova, Anastasiia A and Glumova, Ekaterina D and Tubalova, Maria I and Koksharova, Galina S and Nurislamov, Artem R and Mazurov, Vadim I},
  title = {Targeted Sequencing-Based Re-Evaluation of Candidate Immunogenetic Variants for Biologic Treatment Response and Difficult-to-Treat Rheumatoid Arthritis},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27198800}
}
Kostenlos starten →